Category Archives: Regenerative Medicine

With a leading regenerative medicine portfolio and experienced senior advisory team, Orthocell is well-positioned to drive its products into the US, EU and AU markets.

() has enhanced the quality of its board through the appointment ofexperienced medical technology executive Leslie Wise, JD, as an executive director.

A point of strength for the Perth-based regenerative medicine company is the quality of advisors on its board and the key opinion leaders with whom they are closely connected, who are central to the way they innovate and do business.

As such,Wise, who has more than 20 years of specialist experience working in US reimbursement, life scienceand medtech fields, willstrengthen the company's strategy.

Orthocell managing director Paul Anderson said Wise was ideally suited to support the next phase of the companys development.

He said: We are delighted to welcome Leslie to the Orthocell board.

"Leslie has extensive experience in securing US market access and reimbursement for medical devices as well as serving in various senior management positions across large US medical device and pharmaceutical companies.

Leslies depth of knowledge and expertise is ideally suited to our product range and the next phase of growth for Orthocell.

Wise said: I am very excited to be joining Orthocell at this pivotal stage in the companys development.

Orthocell has one of the most advanced musculoskeletal regenerative medicine portfolios globally and is poised to leverage its impressive clinical evidence to drive towards the US, EU and AUS markets.

The timing could not be better for Orthocell as the broader Orthopaedic sector moves towards biologics and minimally invasive surgeries to deliver higher quality, more efficient and cost-effective solutions.

Leslie Wise, JD,has more than 20 years of specialist experience working in US reimbursement, life scienceand medtech fields

Wise has worked for both medical device and pharmaceutical companies, including Bristol Myers-Squib, Sanofi, Biomet Orthopedics and AngioDynamics, and is currently principal of EvidenceMatters, a Global Market Access consultancy.

Her skill set includes reimbursement, value evidence generation, clinical research strategy and frontline regulatory and payer experience, she has demonstrated experience in strategically integrating outcomes research, health policy analysis, payer insight, patient preference, along with stakeholder engagement and has been instrumental in creating new standards for reimbursement in the medtech space.

In recognition of her expertise, Wise was re-appointed to the Medicare Evidence Development Coverage and Advisory Committee (MEDCAC) for 2018-2020 and She also partnered with Advamed to facilitate the MedTech Value Summit inaugural event in Minneapolis in 2019.

Go here to read the rest:
Orthocell adds to quality of board through appointment of new executive director - Proactive Investors UK

The research report on Regenerative Medicine market provides with a granular evaluation of the business space and contains information regarding the market tendencies such as the prevailing remuneration, revenue estimations, market valuation and market size during the estimated timeframe.

An overview of the performance assessment of the Regenerative Medicine market is mentioned in the report. The document also comprises of insights pertaining to the major market trends and its predicted growth rate. Additional details such as growth avenues as well as hindering factors for this industry landscape are enlisted.

COVID-19, the disease it causes, surfaced in late 2019, and now had become a full-blown crisis worldwide. Over fifty key countries had declared a national emergency to combat coronavirus. With cases spreading, and the epicentre of the outbreak shifting to Europe, North America, India and Latin America, life in these regions has been upended the way it had been in Asia earlier in the developing crisis. As the coronavirus pandemic has worsened, the entertainment industry has been upended along with most every other facet of life. As experts work toward a better understanding, the world shudders in fear of the unknown, a worry that has rocked global financial markets, leading to daily volatility in the U.S. stock markets.

Request Sample Copy of this Report @ https://www.aeresearch.net/request-sample/208516

Pivotal details highlighted in the Regenerative Medicine market report:

In terms of regional frame of reference of the Regenerative Medicine market:

Regenerative Medicine Market Segmentation: Americas, APAC, Europe, Middle East & Africa

A summary of the information enlisted in the Regenerative Medicine market report:

A gist of the Regenerative Medicine market based on the product landscape and application spectrum:

Product landscape:

Product types:

Major aspects included in the report:

Application Landscape:

Application segmentation:

Details mentioned in report:

Additional information offered in the report:

Other details regarding the competitive spectrum of the Regenerative Medicine market:

Vendor base of Regenerative Medicine market:

Major aspects as per the report:

Research objectives:

The report answers important questions that companies may have when operating in the global Regenerative Medicine market. Some of the questions are given below:

Request Customization on This Report @ https://www.aeresearch.net/request-for-customization/208516

Go here to see the original:
Regenerative Medicine Market with Future Prospects, Key Player SWOT Analysis an - News by aeresearch

Contemplated Transaction Would Create a Leading Provider of Advanced Wound Care Solutions that Improve Clinical Outcomes Across the Continuum of Care

SUWANEE, GA, June 10, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc.(OTCQB: SNWV)today announced that it has entered into an exclusive, non-binding letter of intent to acquire Celularitys UltraMIST Ultrasound Healing Therapy asset as well as exclusive partnership rights for Celularitys wound care biologic products. Celularity is a privately held, clinical-stage cell therapeutics company delivering transformative allogeneic cellular therapies, engineered from the postpartum human placenta, in cancer, infectious disease, and degenerative disease. SANUWAVE will conduct an investor teleconference at 9:00 a.m. EDT today to discuss how the contemplated acquisition is expected to broaden its wound care portfolio and enhance its financial profile.

UltraMISTand the Celularity wound care biologic products, Biovance and Interyl, are excellent complements to our dermaPACE System, said Kevin Richardson, SANUWAVE Chief Executive Officer. The contemplated acquisition would bolster our advance wound care portfolio and support our growth strategy to offer comprehensive advanced wound care solutions to improve clinical outcomes across the care pathway. The UltraMIST device is already established in over 900 wound care clinics and SANUWAVE will leverage their sales team to accelerate the penetration of dermaPACE into those facilities.

We are excited about the prospect to bring Celularitys wound care technologies and 25 dedicated wound care professionals to our team, Mr. Richardson continued. Together, we will apply shockwave and ultrasound science to bring differentiated offerings to key wound care solutions worldwide.

The transaction is expected to close in July 2020. The funding for the acquisition will consist of a mix of funded term debt and equity. Existing SANUWAVE shareholders, directors and officers have committed over $5 million at $0.25 per share to assist in completing the transaction.

SANUWAVE has engaged William Blair for investment banking services to arrange, negotiate and assist in the placement of debt capital for the proposed acquisition. William Blair is in advanced discussions with lenders for the debt capital.

The contemplated acquisition is expected to be a transformative event for SANUWAVE and to represent a strategically and financially compelling growth opportunity for the Company. The contemplated transaction would broaden SANUWAVEs addressable market and combines two highly complementary energy transfer technologies with two biologic skin substitute products to create a platform of scale with an end-to-end product offering in the advanced wound care market. Furthermore, it would uniquely position SANUWAVE to address the entire advanced wound care patient pathway from the initial stages of treatment to closure. The treatment combination of UltraMIST and the dermaPACE System would create a significant opportunity to demonstrate improved patient outcomes over the current standard of care, initially for diabetic foot ulcers and across all wound indications in the future.

SANUWAVE will conduct an investor teleconference at 9:00 a.m. EDT today. Investors can access this conference via the following:

Live webcast athttps://www.webcaster4.com/Webcast/Page/2249/35268

Live telephone:

Call 844-602-0380 within the U.S. or +1 862-298-0970 outside the U.S. Please join the call at least 10 minutes before the start time.

Webcast replay:

Go tohttps://www.webcaster4.com/Webcast/Page/2249/35268. The webcast replay will be available until Thursday, September 10, 2020.

Telephone replay:

Call 877-481-4010 within the U.S. or +1 919-882-2331 (for both U.S. and outside U.S., the access code is 35268). The telephone replay will be available until Wednesday, June 17, 2020.

About SANUWAVE Health, Inc.

SANUWAVE Health, Inc. (OTCQB:SNWV) (www.SANUWAVE.com) is a shockwave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVEs portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the bodys normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE, is US FDA cleared for the treatment of Diabetic Foot Ulcers. The device is also CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, South Korea, Australia and New Zealand. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTrondevice, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotronand orthoPACEdevices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVEs shockwave technology for non-medical uses, including energy, water, food and industrial markets.

About Celularity Inc.

Celularity, headquartered in Warren, N.J., is a clinical-stage cell therapeutics company delivering transformative allogeneic cellular therapies derived from the postpartum human placenta. Using proprietary technology in combination with its IMPACT platform, Celularity is the only company harnessing the purity and versatility of placental-derived cells to develop and manufacture innovative, highly scalable off-the-shelf treatments for patients with cancer, infectious diseases, and degenerative diseases. To learn more, please visitwww.celularity.com.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Companys ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Companys product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Companys ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Companys periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.

For additional information about the Company, visitwww.sanuwave.com.

Contact:

Millennium Park Capital LLCChristopher Wynne312-724-7845cwynne@mparkcm.com

SANUWAVE Health, Inc.Kevin Richardson IICEO and Chairman of the Board978-922-2447investorrelations@sanuwave.com

Read more here:
SANUWAVE Health Enters Into Exclusive Letter of Intent to Acquire Celularity's UltraMIST and Exclusive Partnership Rights for Wound Care Biologic...

DUBLIN--(BUSINESS WIRE)--The "Global Regenerative Medicine Partnering Terms and Agreements 2014 to 2020" report has been added to ResearchAndMarkets.com's offering.

The Global Regenerative Medicine Partnering Terms and Agreements 2014-2020 report provides comprehensive understanding and unprecedented access to the regenerative medicine including cell therapy, organ regeneration, stem cells and tissue regeneration partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Regenerative Medicine partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of the latest Regenerative Medicine agreements announced in the life sciences since 2014.

The report takes the reader through a comprehensive review Regenerative Medicine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Regenerative Medicine partnering deals.

The report presents financial deal term values for Regenerative Medicine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Regenerative Medicine partnering field; both the leading deal values and most active Regenerative Medicine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 1100 online deal records of actual Regenerative Medicine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

Key benefits

Key Topics Covered:

Chapter 1 - Introduction

Chapter 2 - Trends in Regenerative Medicine dealmaking

2.1. Introduction

2.2. Regenerative Medicine partnering over the years

2.3. Most active Regenerative Medicine dealmakers

2.4. Regenerative Medicine partnering by deal type

2.5. Regenerative Medicine partnering by therapy area

2.6. Deal terms for Regenerative Medicine partnering

2.6.1 Regenerative Medicine partnering headline values

2.6.2 Regenerative Medicine deal upfront payments7

2.6.3 Regenerative Medicine deal milestone payments

2.6.4 Regenerative Medicine royalty rates

Chapter 3 - Leading Regenerative Medicine deals

3.1. Introduction

3.2. Top Regenerative Medicine deals by value

Chapter 4 - Most active Regenerative Medicine dealmakers

4.1. Introduction

4.2. Most active Regenerative Medicine dealmakers

4.3. Most active Regenerative Medicine partnering company profiles

Chapter 5 - Regenerative Medicine contracts dealmaking directory

5.1. Introduction

5.2. Regenerative Medicine contracts dealmaking directory

Chapter 6 - Regenerative Medicine dealmaking by technology type

Chapter 7 - Partnering resource center

7.1. Online partnering

7.2. Partnering events

7.3. Further reading on dealmaking

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/damlsx

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Read more from the original source:
Insights on Global Regenerative Medicine Partnering Terms and Agreements (2014 to 2020) - ResearchAndMarkets.com - Business Wire

BALTIMORE (WJZ) A stem cell therapy trial for the most critically ill coronavirus patients is underway in Maryland.

Researchers at the University of Maryland School of Medicine are trying to save the maximum number of patients who are significantly sickened by the virus and reduce the mortality rate.

Thanks to a sponsorship by Australian regenerative medicine company Mesoblast, the stem cell therapy trial is underway at several sites across the U.S., including in Maryland.

The therapy involves 300 people hospitalized with COVID-19 with moderate to severe acute respiratory distress syndrome.

These are patients that are intubated, requiring great support for their lung function, Dr. Sunjay Kaushal with the University of Maryland said.

CORONAVIRUS RESOURCES:

COVID-19 patients often become very ill from an escalated immune response referred to as a cytokine storm, which creates high levels of inflammation that can be fatal. The experimental stem cell therapy called remestemcel-L, which has been developed for various inflammatory conditions like what is being seen with the coronavirus, aims to block or mitigate that response, Kaushal said.

Were trying to extrapolate from what they have been shown to be efficacious in trying to treat before and trying to use that type of therapy now for COVID-19 patients, he said.

Once the final results from the trial are available, which could take between six and eight months, researchers hope to reach even more patients.

Were excited, weve seen some early signs that these cells may be efficacious, Kaushal said.

Ultimately, their hope is to provide a new treatment for those suffering from the worst cases of COVID-19.

Were hoping we can save a lot of patients lives, Kaushal said.

For the latest information on coronavirus go to the Maryland Health Departments website or call 211. You can find all of WJZs coverage on coronavirus in Maryland here.

Excerpt from:
Stem Cell Therapy Designed To Treat Severely Ill Coronavirus Patients Being Tested In Maryland - CBS Baltimore

Technavio has been monitoring the regenerative medicine market and it is poised to grow by USD 9.55 billion during 2020-2024, progressing at a CAGR of over 20% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200604005336/en/

Technavio has announced its latest market research report titled Global Regenerative Medicine Market 2020-2024 (Graphic: Business Wire)

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Request for Technavio's latest reports on directly and indirectly impacted markets. Market estimates include pre- and post-COVID-19 impact on the Regenerative Medicine Market Download free sample report

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Allergan Plc, Amgen Inc., Hitachi Chemical Co. Ltd., Integra LifeSciences Holdings Corp., Medtronic Plc, MiMedx Group Inc., Organogenesis Holdings Inc., Smith & Nephew Plc, Takeda Pharmaceutical Co. Ltd., and Zimmer Biomet Holdings Inc. are some of the major market participants. The increasing prevalence of chronic diseases will offer immense growth opportunities. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

The increasing prevalence of chronic diseases has been instrumental in driving the growth of the market. However, uncertainties in regulatory approval might hamper market growth.

Technavio's custom research reports offer detailed insights on the impact of COVID-19 at an industry level, a regional level, and subsequent supply chain operations. This customized report will also help clients keep up with new product launches in direct & indirect COVID-19 related markets, upcoming vaccines and pipeline analysis, and significant developments in vendor operations and government regulations. https://www.technavio.com/report/regenerative-medicine-market-industry-analysis

Regenerative Medicine Market 2020-2024: Segmentation

Regenerative Medicine Market is segmented as below:

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR41171

Regenerative Medicine Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our regenerative medicine market report covers the following areas:

This study identifies the increasing number of clinical trials as one of the prime reasons driving the regenerative medicine market growth during the next few years.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Regenerative Medicine Market 2020-2024: Key Highlights

Table of Contents:

Story continues

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Technology

Customer Landscape

Geographic Landscape

Drivers, Challenges, and Trends

Vendor Landscape

Vendor Analysis

Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200604005336/en/

Contacts

Technavio ResearchJesse MaidaMedia & Marketing ExecutiveUS: +1 844 364 1100UK: +44 203 893 3200Email: media@technavio.com Website: http://www.technavio.com/

Read the original post:
COVID-19 Impact and Recovery Analysis- Regenerative Medicine Market 2020-2024 | Increasing Prevalence of Chronic Diseases to Boost Growth | Technavio...

XconomyBoston

Hearing loss can stem from a variety of reasons, but in rare cases its caused by genetic defects. Akouos is developing a gene therapy to address these problems and its planning an IPO to finance the first tests of its approach in humans.

In paperwork filed with regulators late Friday, Boston-based Akouos set a preliminary $100 million goal for its IPO.

The first target for Akouos is hearing loss due to mutations in the OTOF gene, which encodes a protein called otoferlin. Hearing happens when tiny hair cells in the inner ear pick up vibrations and turn them into signals that the brain interprets as sound. Otoferlin is key to this process, as it enables the sensory cells of the ear to release tiny membranes carrying neurotransmitters, Akouos says in its filing. These neurotransmitters activate auditory neurons, which in turn relay the information to the brain where it is recognized as sound.

Those who have OTOF gene mutations are typically born deaf. There are currently no FDA-approved therapies for this form of hearing loss. The experimental Akouos gene therapy, AK-OTOF, is intended to deliver a functioning version of the OTOF gene with the goal of restoring proper otoferlin expression.

The Akouos therapy is delivered using an engineered version of adeno-associated virus (AAV), an approach used by some FDA-approved gene therapies marketed by other companies for other diseases, as well as for some gene therapies still in development. But the anatomy of the inner ear presents challenges for AAV gene therapy delivery, the company says in its filing. Also, AAV has a limited capacity for carrying a genetic payload.

To overcome those limitations, Akouos uses synthetic AAVs that recreate naturally occurring viruses called ancestral AAVs, which the company says can reach the target in the ear. Furthermore, the company uses a dual vector approach that employs two engineered viruses, each carrying a fragment of the OTOF gene. The Akouos approach to gene therapy is based on the research of Luk Vandenberge, director of the Grousbeck Gene Therapy Center in Boston and a professor at Harvard Medical School. In mouse studies, Akouos says AK-OTOF delivered its genetic payload to the inner ear hair cells, restoring auditory function. Now the company wants to test its technology in humans.

Paperwork seeking FDA permission to start a clinical trial is on track to be submitted in 2021, Akouos says in its filing. If all goes as planned, the company expects to report preliminary data from the clinical trial the following year.

Akouos isnt the only company developing new treatments for inherited forms of hearing loss.Decibel Therapeutics is also developing a gene therapy to address the same genetic protein deficiency that Akouos is targeting. The Boston-based companys experimental gene therapy, DB-OTO, is in preclinical development with partner Regeneron Pharmaceuticals (NASDAQ: REGN). Otonomy (NASDAQ: OTIC), in San Diego, is advancing a preclinical gene therapy program intended to address hearing loss caused by mutations in another key gene, GJB2. Frequency Therapeutics (NASDAQ: FREQ) is addressing hearing loss caused by the loss of hair cells in the inner ear. The Woburn, MA-based company is developing a regenerative medicine approach that coaxes the regrowth of these hairs.

Akouos was founded in 2016 and unveiled $50 million in financing two years later. In March, the company closed a $105 million Series B round of financing that added crossover investors. The biggest shareholders in Akouos prior to the IPO are 5AM Ventures and New Enterprise Associates, which own about 21.6 and 18.5 percent respectively, according to the filing.

Akouos has applied for a listing on the Nasdaq under the stock symbol AKUS. If the company successfully completes the IPO, it says it will apply the capital toward clinical development of AK-OTOF, as well as the preclinical development of other programs in its pipeline.

Image: iStock/iLexx

Frank Vinluan is an Xconomy editor based in Research Triangle Park. You can reach him at fvinluan@xconomy.com.

Originally posted here:
Akouos Aims for an IPO to Advance Hearing Loss Gene Therapy to Clinic - Xconomy

Prof Volker ter Meulen, Co-chair of the EASAC-FEAM working group and past president of EASAC, said: Stem cell and gene-based therapies hold great medical promises. But we are alarmed over a trend to lower requirements of evidence. Also, we see an increasing problem of commercial clinics offering unregulated products and services.

The Academies say the idea of regenerative medicine is to tackle diseases which up to now are incurable. According to the report, cosmetic applications are inappropriate for the time being.

So far, regenerative medicine has proven itself only in few specific clinical indications, for example for skin disorders. Yet, we see an increasing number of unregulated clinics promising a wide range of benefits based on poorly characterised medicinal products with little evidence of effectiveness. They usually advertise their services via the internet with the primary intention of financial profit, explains EASAC Biosciences Programme Director, Dr Robin Fears.

The scientists urge the EU to resist the pressure and put patients first:When countries lower regulatory standards in their eagerness to support national economic interests, it is even more important for the EU as a major global player to defend the principles of international cooperation in health regulation, says Prof George Griffin, Co-chair of the working group and President of FEAM.

We all want cures to be available in the shortest time frame possible. But our analysis and recommendations aim at ensuring that regulatory procedures are robust, transparent and evidence-based, concludes Cossu. Scientific research and proof are more important than ever. The EU and national regulators should be wary of not undermining public trust in science.

Go here to see the original:
Miracle cures and fast-track approval threatens medical advances, say scientists - The University of Manchester

A new market report by Verified Market Research on the Regenerative Medicine Market has been released with reliable information and accurate forecasts for a better understanding of the current and future market scenarios. The report offers an in-depth analysis of the global market, including qualitative and quantitative insights, historical data, and estimated projections about the market size and share in the forecast period. The forecasts mentioned in the report have been acquired by using proven research assumptions and methodologies. Hence, this research study serves as an important depository of the information for every market landscape. The report is segmented on the basis of types, end-users, applications, and regional markets.

The research study includes the latest updates about the COVID-19 impact on the Regenerative Medicine sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.verifiedmarketresearch.com/download-sample/?rid=7157&utm_source=COD&utm_medium=007

The report also emphasizes the initiatives undertaken by the companies operating in the market including product innovation, product launches, and technological development to help their organization offer more effective products in the market. It also studies notable business events, including corporate deals, mergers and acquisitions, joint ventures, partnerships, product launches, and brand promotions.

Leading Regenerative Medicine manufacturers/companies operating at both regional and global levels:

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

The report also focuses on the global industry trends, development patterns of industries, governing factors, growth rate, and competitive analysis of the market, growth opportunities, challenges, investment strategies, and forecasts till 2026. The Regenerative Medicine Market was estimated at USD XX Million/Billion in 2016 and is estimated to reach USD XX Million/Billion by 2026, expanding at a rate of XX% over the forecast period. To calculate the market size, the report provides a thorough analysis of the market by accumulating, studying, and synthesizing primary and secondary data from multiple sources.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=7157&utm_source=COD&utm_medium=007

The market is predicted to witness significant growth over the forecast period, owing to the growing consumer awareness about the benefits of Regenerative Medicine. The increase in disposable income across the key geographies has also impacted the market positively. Moreover, factors like urbanization, high population growth, and a growing middle-class population with higher disposable income are also forecasted to drive market growth.

According to the research report, one of the key challenges that might hinder the market growth is the presence of counter fit products. The market is witnessing the entry of a surging number of alternative products that use inferior ingredients.

Key factors influencing market growth:

Reasons for purchasing this Report from Verified Market Research

Customized Research Report Using Corporate Email Id @ https://www.verifiedmarketresearch.com/product/global-regenerative-medicine-market/?utm_source=COD&utm_medium=007

Customization of the Report:

Verified Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

To summarize, the Regenerative Medicine market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

Continue reading here:
Regenerative Medicine Market 2019 Break Down by Top Companies, Countries, Applications, Challenges, Trends, Opportunities and Forecast 2026 - Cole of...

Visit the News Hub

Anatomy association recognizes research into spinal cord regeneration

Mokalled

Mayssa H. Mokalled, PhD, an assistant professor of developmental biology at Washington University School of Medicine in St. Louis, has received the 2020 H.W. Mossman Award in Developmental Biology from the American Association for Anatomy.

This award recognizes outstanding researchers in developmental biology who, though still in the early stages of their careers, already have made important contributions to the field and show promise for future accomplishments.

Mokalled studies spinal cord regeneration in zebrafish, a model organism that has the capacity to heal even severe spinal cord injuries. Her lab is investigating whether the regenerative capacity of zebrafish is conserved in mammals but masked by other molecular pathways. Specifying the details of the cellular and molecular pathways of spinal cord regeneration in zebrafish could provide insight into the potential for such regeneration in mammals.

Link:
Mokalled receives national early career award - Washington University School of Medicine in St. Louis